AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...

Over the past few years, API security has gone from a relatively niche concern to a headline issue. A slew of high-profile breaches and compliance mandates like PCI DSS 4.0 have woken security teams ...

For brands to thrive in today's ever-changing landscape, they must cultivate a deep understanding of their purpose. This ...

B y any measure, there is an enormous number of programming languages. Some lists contain hundreds, while the Historical ...

Welcome to this week’s ForbesWomen newsletter, which every Thursday brings news about the world’s top female entrepreneurs, ...

In a Q&A, Recursion’s incoming CEO acknowledges hype around the idea of using AI to expedite drug development, and says it's ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best mid cap stocks to buy according to hedge funds.

This week, my colleagues and I scheduled 30 minutes to talk with Mark Cuban for “The Readout LOUD” podcast. The conversation ...